Business Parks & Science Centres

 
 
 

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

Microbiotica Ltd.. (10/24/18). "Press Release: Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital Fund". Cambridge.

Organisation Organisation Microbiotica Ltd.
Product Product microbiomics
Index terms Index term Microbiotica–BPCE: investment, 201810 investment £4m by Seventure Partners’ Health for Life Capital Fund
  Index term 2 Microbiotica–Wellcome Trust: investment, 20810 exising investor Wellcome Sanger Institute
Persons Person Romanos, Mike (Microbiotica 201612– CEO before Crescendo Biologics CEO before CSO since 5/09 before GSK)
  Person 2 Wilcock, Iain (200811– BPCE Investment Advisor to Seventure Partners + Vela Ventures before Quester)
     


Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised to date to £12m.

The company, which was founded in 2016 to develop transformational technology developed at the Sanger Institute, has made rapid progress in developing a unique capability to culture, characterise and phenotype the majority of a patient’s gut bacteria, enabling the precise association of bacteria to function at clinical trial scale.

Mike Romanos, CEO of Microbiotica, said: “The microbiome represents a paradigm shift which requires the re-evaluation of almost every aspect of biomedicine. Microbiotica’s world-leading microbiome culture collection and reference genome database enable unprecedented precision of gut bacterial identification and provide the foundation for the company to develop its own pipeline of microbiome-derived therapeutics and biomarkers. We look forward to working with Iain Wilcock, who will join the Microbiotica Board of Directors, and with the broader Seventure team led by Isabelle De Cremoux.”

Isabelle de Cremoux, CEO of Seventure Partners, said: “We have watched Microbiotica make dramatic progress in implementing its vision and believe the company has developed a powerful set of capabilities for biomarker and therapeutic discovery in the microbiome field. We believe that the company has the potential to become a global leader in this fast-growing area, led by a strong and ambitious management team with considerable depth of expertise and experience, and are excited to be involved in helping realise this potential.”

As a result of this investment, Microbiotica’s shareholders comprise the Founders, Wellcome Sanger Institute, Cambridge Innovation Capital, IP Group plc and Seventure Partners.


Media Contact Information:

Microbiotica
Rowena Gardner
rgardner@microbiotica.com
+44 1223 786063 / +44 7801 480569

Instinctif Partners (for media enquiries):
Sue Charles/Gemma Harris
microbiotica@instinctif.com
+44 20 7866 7860

   
Record changed: 2018-11-03

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Microbiotica Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top